MUMBI KAIRU: Open Payments
NPI 1235267006 · PASADENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,408 in 141 payments from 14 companies in 2025. Trend: 2023 $947 · 2024 $1,616 · 2025 $3,408
Food & beverage: $3,206Education: $203
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 20 | $523 |
| Teva Pharmaceuticals USA, Inc. | 18 | $511 |
| Janssen Pharmaceuticals, Inc | 21 | $420 |
| Neurocrine BioSciences, Inc. | 14 | $380 |
| ABBVIE INC. | 12 | $302 |
| Alkermes, Inc. | 10 | $282 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $280 |
| Vanda Pharmaceuticals Inc. | 9 | $245 |
| Otsuka America Pharmaceutical, Inc. | 8 | $218 |
| Axsome Therapeutics, Inc. | 13 | $167 |
Products named: COBENFY, INGREZZA, VRAYLAR, CAPLYTA, ARISTADA, FANAPT, SPRAVATO, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
